ANDA 218977

**ANDA APPROVAL**

Apotex Corp.
U.S. Agent for Apotex Inc.
2400 North Commerce Parkway
Suite 400
Weston, FL 33326
Attention: Kiran Krishnan
Senior Vice President, GRA

Dear Kiran Krishnan:

This letter is in reference to your abbreviated new drug application (ANDA) received for review on December 14, 2023, submitted pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for Prucalopride Tablets, 1 mg and 2 mg.

Reference is also made to the complete response letter issued by this office on December 13, 2024, and to any amendments thereafter.

We have completed the review of this ANDA and have concluded that adequate information has been presented to demonstrate that the drug meets the requirements for approval under the FD&C Act. Accordingly the ANDA is **approved**, effective on the date of this letter. We have determined your Prucalopride Tablets, 1 mg and 2 mg to be bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Motegrity Tablets, 1 mg and 2 mg, of Takeda Pharmaceuticals U.S.A. Inc., NDA - 210166.

Reference is also made to FDA's Competitive Generic Therapy Designation – Grant letter dated December 4, 2023.

We note that Apotex Inc. (Apotex) was granted a Competitive Generic Therapy (CGT) designation for Prucalopride Tablets, 1 mg and 2 mg. However, Apotex is not a "first approved applicant" for such Competitive Generic Therapies, as defined in section 505(j)(5)(B)(v)(III) of the FD&C Act. Therefore, your drug product is not eligible for CGT exclusivity under section 505(j)(5)(B)(v) of the FD&C Act.

Please note that if FDA requires a Risk Evaluation and Mitigation Strategy (REMS) for a listed drug, an ANDA referencing that listed drug also will be required to have a REMS. See section 505-1(i) of the FD&C Act.

## COMPENDIAL STANDARDS

A drug with a name recognized in the official United States Pharmacopeia or official National Formulary (USP-NF) generally must comply with the compendial standard for strength, quality, and purity, unless the difference in strength, quality, or purity is plainly stated on its label (see FD&C Act § 501(b), 21 USC 351(b)). FDA typically cannot share application-specific information contained in submitted regulatory filings with third parties, which includes USP-NF. To help ensure that a drug continues to comply with compendial standards, application holders may work directly with USP-NF to revise official USP monographs. More information on the USP-NF is available on USP's website as https://www.uspnf.com/.

## REQUIREMENTS AND RECOMMENDATIONS POST APPROVAL

Under applicable statutes, regulations, and guidances, your ANDA may be subject to certain requirements and recommendations post approval, including requirements regarding changes to approved ANDAs, postmarketing reporting, promotional materials, and annual facility fees, among others. For information on post-approval requirements and recommendations for ANDAs and a list of resources for ANDA holders, we refer you to https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/requirements-and-resources-approved-andas.

Sincerely yours,

*{See appended electronic signature page}*

For Malik Imam, PharmD, MBA
CDR, United States Public Health Service
Deputy Director
Office of Regulatory Operations
Office of Generic Drugs
Center for Drug Evaluation and Research

Catherine Poole

Digitally signed by Catherine Poole
Date: 6/24/2025 08:18:18AM
GUID: 5407887a000a1c0c26055eafb8e3258a